Success Metrics

Clinical Success Rate
93.5%

Based on 29 completed trials

Completion Rate
94%(29/31)
Active Trials
0(0%)
Results Posted
59%(17 trials)
Terminated
2(6%)

Phase Distribution

Ph not_applicable
2
6%
Ph phase_2
2
6%
Ph phase_1
12
33%
Ph phase_4
1
3%
Ph phase_3
18
50%

Phase Distribution

12

Early Stage

2

Mid Stage

19

Late Stage

Phase Distribution35 total trials
Phase 1Safety & dosage
12(34.3%)
Phase 2Efficacy & side effects
2(5.7%)
Phase 3Large-scale testing
18(51.4%)
Phase 4Post-market surveillance
1(2.9%)
N/ANon-phased studies
2(5.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.3%

29 of 34 finished

Non-Completion Rate

14.7%

5 ended early

Currently Active

0

trials recruiting

Total Trials

36

all time

Status Distribution
Completed(29)
Terminated(5)
Other(2)

Detailed Status

Completed29
Withdrawn3
unknown2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
36
Active
0
Success Rate
93.5%
Most Advanced
Phase 4

Trials by Phase

Phase 112 (34.3%)
Phase 22 (5.7%)
Phase 318 (51.4%)
Phase 41 (2.9%)
N/A2 (5.7%)

Trials by Status

unknown26%
terminated26%
withdrawn38%
completed2981%

Recent Activity

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT00681538Phase 3

A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)

Completed
NCT00711646Phase 3

A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.

Completed
NCT00702468Phase 3

Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis

Completed
NCT00674609Phase 3

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy

Completed
NCT00713817Phase 3

A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain

Completed
NCT00678795Phase 3

A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis

Completed
NCT01599234Phase 3

A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis

Completed
NCT00710424Phase 3

A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy

Completed
NCT00675948Phase 3

Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain

Completed
NCT00710554Phase 3

A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia

Completed
NCT00713323Phase 3

A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.

Completed
NCT00711880Phase 3

A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.

Completed
NCT01322464Phase 1

Study to Assess Food Effect on Sativex Bioavailability

Completed
NCT01323569Phase 1

Abuse Potential of Sativex

Completed
NCT01964547Phase 4

A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients

Completed
NCT01604265Phase 3

A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis

Completed
NCT01812616Phase 1

A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients

Completed
NCT01812603Phase 1

A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

Completed
NCT01887301Phase 1

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Completed
NCT01898520Phase 3

A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years

Completed

Drug Details

Intervention Type
DRUG
Total Trials
36